Related references
Note: Only part of the references are listed.Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia
Jennifer Hibma et al.
CLINICAL PHARMACOKINETICS (2019)
CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (AdcetrisA®), is Associated with Microtubule Disruption
Francis S. Wolenski et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
Auayporn Nademanee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE
Elias J. Jabbour et al.
CANCER (2018)
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
Marek Trneny et al.
HAEMATOLOGICA (2018)
Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients
Tiina Moilanen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Tomomi Nakayama Iwata et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
Marek Trneny et al.
HAEMATOLOGICA (2018)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Hiroji Iwata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Nirnoy Dan et al.
PHARMACEUTICALS (2018)
Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned
William D. Hedrich et al.
CLINICAL PHARMACOKINETICS (2018)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2017)
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
LANCET HAEMATOLOGY (2017)
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Daniel J. DeAngelo et al.
BLOOD ADVANCES (2017)
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
Baiteng Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
Bertrand Coiffier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma
Jamie E. Flerlage et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma
Eunhye Oak et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer
Sung-Bae Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine
Jeremy Force et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Sergio Amadori et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis
Kai Shen et al.
SCIENTIFIC REPORTS (2016)
Targeting B-cell maturation antigen in multiple myeloma
Yu-Tzu Tai et al.
IMMUNOTHERAPY (2015)
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
Current ADC Linker Chemistry
Nareshkumar Jain et al.
PHARMACEUTICAL RESEARCH (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature
Stefan K. Alig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody-Drug Conjugates
Samantha M. Gromek et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
Mitul D. Gandhi et al.
BLOOD (2014)
Progressive Multifocal Leukoencephalopathy Associated With Brentuximab Vedotin Therapy A Report of 5 Cases from the Southern Network on Adverse Reactions (SONAR) Project
Kenneth R. Carson et al.
CANCER (2014)
A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Vincent Ribrag et al.
CLINICAL CANCER RESEARCH (2014)
Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
Alan S. Gamis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Nancy L. Bartlett et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review
Michael D. DeVita et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.
Johanna Bendell et al.
CANCER RESEARCH (2013)
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies
Tae H. Han et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper
Boris Gorovits et al.
BIOANALYSIS (2013)
TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
K. Haddley
DRUGS OF TODAY (2013)
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter et al.
NATURE BIOTECHNOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
In Vitro Characterization of the Drug-Drug Interaction Potential of Catabolites of Antibody-Maytansinoid Conjugates
John A. Davis et al.
DRUG METABOLISM AND DISPOSITION (2012)
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart
CLINICAL CANCER RESEARCH (2011)
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)
Sergio Amadori et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
JA Dowell et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
